- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.
With shares of Gilead Sciences falling in Wednesday trading after reporting better-than-expected earnings, TheStreet senior columnist Adam Feuerstein breaks down what has investors spooked.
TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off Monday in San Francisco.
A dirty divorce for one of Wall Street's top bankers just got messier.
Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis.
The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. The selling has gained in volume and speed as no one wants to be the last trader standing.
Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.
It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.
The only part of Perrigo actually moving to Ireland post the Elan deal is its bank account, says Adam Feuerstein, Sr. Columnist at TheStreet.
Alnylam Pharmaceuticals upcoming meeting is the next big thing in biotech, says TheStreet Sr. columnist Adam Feuerstein.